BTIG analyst Thomas Shrader assumes coverage on Celgene (NASDAQ: CELG) with a Neutral rating.The analyst says Revlimid is growing "briskly ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE